Jame Abraham, MD of Cleveland Clinic discusses his hopes for NSABP-FB10 becoming a Phase II and Phase III trial for patients with breast cancer. He also discusses how to manage the diarrhea and nausea in patients who underwent this study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Will NSABP FB-10 Become a Phase III Trial?
